Literature DB >> 31484635

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis.

Mohamad A Meybodi1, Wenhao Cao2, Leo Luznik3, Asad Bashey4, Xu Zhang5, Rizwan Romee6, Wael Saber7, Mehdi Hamadani7, Daniel J Weisdorf1, Haitao Chu2, Armin Rashidi1.   

Abstract

HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ~50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.
© 2019 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31484635      PMCID： PMC6737418          DOI： 10.1182/bloodadvances.2019000614

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  25 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

Review 2.  Evaluating non-randomised intervention studies.

Authors:  J J Deeks; J Dinnes; R D'Amico; A J Sowden; C Sakarovitch; F Song; M Petticrew; D G Altman
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

3.  Outlier and influence diagnostics for meta-analysis.

Authors:  Wolfgang Viechtbauer; Mike W-L Cheung
Journal:  Res Synth Methods       Date:  2010-10-04       Impact factor: 5.273

4.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

5.  Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index.

Authors:  Asad Bashey; Xu Zhang; Katelin Jackson; Stacey Brown; Michelle Ridgeway; Melhem Solh; Lawrence E Morris; H Kent Holland; Scott R Solomon
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-07       Impact factor: 5.742

6.  Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.

Authors:  Melhem Solh; Xu Zhang; Katelin Connor; Stacey Brown; Scott R Solomon; Lawrence E Morris; H Kent Holland; Asad Bashey
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-14       Impact factor: 5.742

7.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

Authors:  Lauri M Burroughs; Paul V O'Donnell; Brenda M Sandmaier; Barry E Storer; Leo Luznik; Heather J Symons; Richard J Jones; Richard F Ambinder; Michael B Maris; Karl G Blume; Dietger W Niederwieser; Benedetto Bruno; Richard T Maziarz; Michael A Pulsipher; Finn B Petersen; Rainer Storb; Ephraim J Fuchs; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

8.  Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Authors:  Yvette L Kasamon; Javier Bolaños-Meade; Gabrielle T Prince; Hua-Ling Tsai; Shannon R McCurdy; Jennifer A Kanakry; Gary L Rosner; Robert A Brodsky; Karlo Perica; B Douglas Smith; Douglas E Gladstone; Lode J Swinnen; Margaret M Showel; William H Matsui; Carol Ann Huff; Ivan Borrello; Keith W Pratz; Michael A McDevitt; Ivana Gojo; Amy E Dezern; Satish Shanbhag; Mark J Levis; Leo Luznik; Richard F Ambinder; Ephraim J Fuchs; Richard J Jones
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21

10.  A re-evaluation of random-effects meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson; David J Spiegelhalter
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-01       Impact factor: 2.483
View more
  6 in total

1.  Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.

Authors:  Hirohisa Nakamae
Journal:  Int J Hematol       Date:  2022-08-05       Impact factor: 2.319

2.  Real-world experience: Introduction of T cell replete haploidentical transplantations in a single center.

Authors:  Gwendolyn van Gorkom; Evy Billen; Catharina Van Elssen; Michel van Gelder; Gerard Bos
Journal:  EJHaem       Date:  2021-05-26

Review 3.  Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.

Authors:  Bruce R Blazar; Geoffrey R Hill; William J Murphy
Journal:  Nat Rev Clin Oncol       Date:  2020-04-20       Impact factor: 66.675

Review 4.  Donor specific HLA antibody in hematopoietic stem cell transplantation: Implications for donor selection.

Authors:  Scott M Krummey; Alison J Gareau
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

5.  A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies.

Authors:  Hirohisa Nakamae; Hiroshi Okamura; Asao Hirose; Hideo Koh; Yasuhiro Nakashima; Mika Nakamae; Mitsutaka Nishimoto; Yosuke Makuuchi; Masatomo Kuno; Naonori Harada; Teruhito Takakuwa; Masayuki Hino
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

Review 6.  Haploidentical Stem Cell Transplantation in Lymphomas-Expectations and Pitfalls.

Authors:  Jacopo Mariotti; Stefania Bramanti; Armando Santoro; Luca Castagna
Journal:  J Clin Med       Date:  2020-11-07       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.